NASDAQ$SERA
Sera Prognostics Inc-A · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Sera Prognostics' financial performance was impacted by revenue adjustments, but the company progressed in setting the stage for a potential revenue inflection by submitting data for publication and exploring growth opportunities.
Sera Prognostics reported a decrease in revenue due to adjustments related to old accounts, resulting in net revenue of nil for Q1 2024. However, the company reduced operating expenses by 20% and narrowed its net loss by 24%. They are focusing on future revenue growth through data publication, new commercial opportunities, and international market exploration.
- Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication.
- Shipped first ambient whole blood collection kits, expected to reduce cost of goods sold and increase lab processing capacity.
- Collaborating on state implementation programs to promote health equity and improve pregnancy care.
- Exploring attractive international markets with a significant number of premature births.
Headline financials
Revenue & EPS history
Sera Prognostics · Revenue · Quarterly
$0
Forward guidance
Sera Prognostics is focused on future revenue growth, margin improvement, and efficient test processing.
Tailwinds
- New ambient whole blood collection kits are expected to reduce cost of goods sold.
- New ambient whole blood collection method allows access to more patients.
- Exploring growth opportunities where PreTRM can make a sizeable difference.
- Data submission for publication is expected to enhance the evidence portfolio.
- Targeted state implementation programs to promote health equity.
Headwinds
- Revenue for the quarter was impacted by revenue adjustments related to old accounts.
- Need for broad scientific and market acceptance of the PreTRM Test.
- Revenues from the PreTRM Test representing substantially all Company revenues to date.
- Potential third-party payer coverage and reimbursement.
- Potential competition.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-1.9%
Avg return
Earnings day
-3.5%
Avg return
5 days after
-3.3%
Avg return
30 days after
36%
8 / 22 earnings
Positive
+14.3%
Q3 2022
Best reaction
-11.7%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -8.0% | +18.1% | |
| Q4 2025 | -7.7% | +6.3% | +20.4% | |
| Q3 2025 | +1.7% | +8.5% | +19.0% | |
| Q1 2025 | -11.7% | -2.1% | -35.4% | |
| Q4 2024 | -5.1% | -2.2% | -17.9% | |
| Q3 2024 | -0.3% | -2.7% | -3.9% | |
| Q2 2024 | +0.0% | -1.2% | -2.2% | |
| Q1 2024 | +3.3% | -4.0% | -13.6% | |
| Q4 2023 | +3.4% | +1.1% | +7.7% | |
| Q3 2023 | -3.2% | -6.4% | +130.9% | |
| Q2 2023 | +0.8% | -10.1% | -39.9% | |
| Q1 2023 | -0.8% | -2.8% | -13.0% | |
| Q4 2022 | -10.0% | -9.5% | -22.3% | |
| Q3 2022 | +14.3% | +11.1% | -4.0% | |
| Q2 2022 | -4.1% | -6.3% | -27.3% | |
| Q1 2022 | -7.6% | -17.1% | -32.7% | |
| Q4 2021 | +3.6% | +0.3% | -39.3% | |
| Q3 2021 | +0.3% | -0.8% | -8.2% | |
| Q3 2020 | +0.3% | -0.8% | -8.2% | |
| Q2 2021 | -4.8% | -9.9% | +0.0% | |
| Q1 2021 | -4.8% | -9.9% | +0.0% | |
| Q4 2020 | -4.8% | -9.9% | +0.0% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro